Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jun;37(3):497-506.
doi: 10.1007/s10557-021-07259-y. Epub 2021 Nov 12.

Early Trimetazidine Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Reduces Myocardial Infarction Size

Geng Qian  1 , Xin A  2 , Xiaosi Jiang  2 , Zichao Jiang  2 , Tao Li  2 , Wei Dong  2 , Jun Guo  2 , Yundai Chen  3
Affiliations
Randomized Controlled Trial

Early Trimetazidine Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Reduces Myocardial Infarction Size

Geng Qian et al. Cardiovasc Drugs Ther. 2023 Jun.

Abstract

Purpose: Trimetazidine, a metabolic agent with anti-ischemic effects, was reported to reduce reperfusion injury in animal models. In this randomized double-blind placebo-controlled trial, we investigated the effects of trimetazidine on the reduction of infarction size in patients undergoing revascularization for ST segment elevation myocardial infarction (STEMI).

Methods: Patients with STEMI randomly received trimetazidine (n = 87) or placebo (n = 86) before primary percutaneous coronary intervention (PCI), and subsequently received oral trimetazidine or placebo for 12 months after reperfusion. The predefined primary endpoint was infarction size on cardiac magnetic resonance (CMR) performed at 7 days after primary PCI. The trial was registered on www.

Clinicaltrials: gov (registration number: NCT02826616).

Results: The clinical characteristics of the patients in both groups were well-matched at baseline. At 7 days after primary PCI, the percentage and absolute infarction size in the trimetazidine group were significantly smaller than those in the control group (22% ± 12% [n = 74] vs. 27% ± 13% [n = 74], p = 0.011 and 28 ± 18 g [n = 74] vs. 35 ± 19 g [n = 74], p = 0.022, respectively), and the incidence of myocardial microvascular obstruction (MVO) measured by CMR was significantly reduced in the trimetazidine group (29.7% [22/74] vs. 52.7% [39/74], p = 0.005). The myocardial salvage index (MSI) measured by CMR was significantly higher in the trimetazidine group (48% ± 20% vs. 39% ± 20%, p = 0.008). The incidence of readmission due to aggravated heart failure did not differ significantly between the trimetazidine group and the control group (8.0% vs. 14.0%, p = 0.234).

Conclusions: In patients with STEMI undergoing primary PCI, early trimetazidine before reperfusion reduced myocardial infarction size and MVO, and improved MSI.

Keywords: Cardiac magnetic resonance; Infarction size; Myocardial infarction; Percutaneous coronary intervention; Trimetazidine.

PubMed Disclaimer

References

    1. Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, et al. Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiac miRNA21 expression, Akt and the Bcl2/Bax pathway. Mol Med Rep. 2016;14(5):4216–22. - DOI - PubMed - PMC
    1. Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, et al. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65:122–30. - DOI - PubMed
    1. Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, et al. Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl). 2018;96:791–806. - DOI - PubMed
    1. Zhong Y, Zhong P, He S, Zhang Y, Tang L, Ling Y, et al. Trimetazidine protects cardiomyocytes against hypoxia/reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J Cardiovasc Pharmacol. 2017;69:389–97. - DOI - PubMed
    1. Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta-analysis. Cardiology. 2016;135:188–95. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources